Convalescent Plasma / Stony Brook Medicine - LARVOL DELTA

Acute transverse myelitis (ATM) associated with COVID 19 infection and vaccination, A case report and literature review. (AAN 2023) - "No cases reported the use of convalescent plasma therapy after infection...One case reported a positive response after treatment with eculizumab, and another with infliximab...Almost all of them reported responding with steroids except one case reported fatal after 58th day after vaccination. Conclusions TM, post-COVID-19 infection, has been described in multiple cases, as well as being a rare complication of COVID-19 vaccination."

Clinical • Review • CNS Disorders • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pediatrics

Comparison of Two Waves of COVID-19 in Critically Ill Patients: A Retrospective Observational Study. (PubMed, Int J Nephrol) - "Remdesivir (adj. HR 0.5; 95% CI 0.3-0.7; p < 0.01) decreased the risk of AKI, and convalescent plasma (adj...Our study shows a decrease in the incidence of AKI in critically ill patients, however, the reason for this decrease is still unknown. Studies comparing the waves of the pandemic would not only help in understanding disease evolution but also to develop tailored management strategies."

Journal • Observational data • Retrospective data • Acute Kidney Injury • Chronic Kidney Disease • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases

Comparison of Neutralizing Capacity of Plaque Reduction Assay to Novel Pseudovirus Assay for SARS-CoV-2 (ASA 2021) - "Therefore, the purpose of this analysis was to compare neutralization capacity of plasma, obtained for use in a randomized trial of convalescent plasma, using these two assays... 8 unique plasma samples (4 high and 4 medium) were tested in both the pseudovirus and plaque assays. These samples had a mean NT50 dilution of 1:559 in the plaque assay and 1:267 in the pseudovirus assay. The assays' NT50 values correlated better for high OD density samples, i.e. the mean (95% CI) ratio of NT50s from plaque/pseudovirus assays was 2.31 (0.73, 3.89) for the high group vs 4.08 (0.03, 8.13) for the medium group."

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

HLA B53 is associated with a poor outcome in black COVID-19 patients. (PubMed, Hum Immunol) - "Multi-variate analysis indicated that HLA B53 positive Black hospitalized COVID-19 patients were at a 7.4 fold greater risk of death than Black COVID-19 patients who were B53 negative. Consideration for accelerated vaccination and treatment should be given to HLA B53 positive Black COVID19 patients."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation

[VIRTUAL] An Interesting Case of COVID-19 Induced Hypercoagulability Manifesting as Pulmonary Embolism and Apical Left Ventricular Thrombus (ATS 2021) - "The patient received treatment with convalescent plasma, Remdesivir, and dexamethasone as per our institutional protocol and started on unfractionated heparin for anticoagulation. She was discharged on enoxaparin as per the patient’s preference on a stable condition with close cardiology follow up...Early recognition of LV thrombus and treatment with anticoagulation is of paramount importance to reducing stroke risk and systemic embolization. The detection of LV thrombus mandates anticoagulation with warfarin or heparin due to insufficient evidence to support the use of direct oral anticoagulants."

Clinical • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Fatigue • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Myocardial Infarction • Novel Coronavirus Disease • Pneumonia • Pulmonary Embolism • Respiratory Diseases • Venous Thromboembolism

Convalescent Plasma vs. Standard Plasma for COVID-19 (clinicaltrials.gov) - P1/2; N=82; Terminated; Sponsor: Stony Brook University; N=500 ➔ 82; Trial completion date: Aug 2021 ➔ Feb 2021; Enrolling by invitation ➔ Terminated; Trial primary completion date: Apr 2021 ➔ Jan 2021; Insufficient eligible and consenting patients

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial. (PubMed, Crit Care Med) - "Administration of convalescent plasma to hospitalized patients with coronavirus disease 2019 infection increased antibodies to severe acute respiratory syndrome coronavirus disease 2 but was not associated with improved outcome."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

Convalescent Plasma vs. Standard Plasma for COVID-19 (clinicaltrials.gov) - P1/2; N=500; Enrolling by invitation; Sponsor: Stony Brook University

Clinical • New P1/2 trial